Compare ANPA & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ANPA | ELOX |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Hong Kong | United States |
| Employees | 32 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 41.0M |
| IPO Year | 2024 | 2013 |
| Metric | ANPA | ELOX |
|---|---|---|
| Price | $2.62 | $15.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 49.0K | 36.6K |
| Earning Date | 02-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.81 | $10.00 |
| 52 Week High | $180.64 | $23.40 |
| Indicator | ANPA | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 27.32 | 49.97 |
| Support Level | N/A | $15.21 |
| Resistance Level | $4.59 | $19.66 |
| Average True Range (ATR) | 0.34 | 2.75 |
| MACD | -0.12 | -0.29 |
| Stochastic Oscillator | 2.41 | 26.79 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.